Salomon & Ludwin
CORT icon

Salomon & Ludwin’s Corcept Therapeutics CORT Stock Holding History

Salomon & Ludwin’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-895
Closed -$79.2K – 1722
2026
Q2 		$79.2K Sell
895
-168
-16% -$10.1K 0.01% 339
2026
Q1 		$45.2K Buy
1,063
+402
+61% +$15K ﹤0.01% 534
2025
Q4 		$23.1K Buy
661
+28
+4% +$2.2K ﹤0.01% 788
2025
Q3 		$55.8K Buy
+633
New +$45.8K 0.01% 355

Other funds holding CORT

Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return

Salomon & Ludwin's CORT Position: Q3 2026 in Review

Salomon & Ludwin sold out of Corcept Therapeutics (CORT) in Q3 2026, closing a stake of 895 shares — an estimated $79.2K sold.

Salomon & Ludwin first reported a position in CORT in Q3 2025 and held it in 4 quarters. The position peaked at $79.2K in Q2 2026. 216 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Salomon & Ludwin reported no remaining Corcept Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Salomon & Ludwin sold 895 Corcept Therapeutics shares in Q3 2026, an estimated $79.2K.
  • Salomon & Ludwin first reported a position in Corcept Therapeutics in Q3 2025 and held it in 4 quarters.
  • Salomon & Ludwin's Corcept Therapeutics position peaked at $79.2K in Q2 2026.
  • 216 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Salomon & Ludwin's 13F filing for Q3 2026, filed 29 Oct 2026.